Sep 16,2021 10:52 AM
Ibuprofen and Famotidine Tablets (RLD: Duexis) had estimated annual sales of USD 765 million in the U.S. (IQVIA MAT July 2021).
|Resolution Type||Description Of Resolution||IiAS Recommendation|
|Name||LTP||PE||Mar Cap||NP Qtr||Div. Yld||Sales Qtr||BV|
|Sun Pharmaceuticals Industries Ltd||769.90||87.73||184,808.78||419.30||0.97||3,312.54||104.36|
|Divis Laboratories Ltd||5,122.80||67.55||136,069.90||551.97||0.39||1,950.16||349.25|
|Dr Reddys Laboratories Ltd||4,884.55||49.31||81,345.47||413.40||0.51||3,410.10||1,032.60|
|Gland Pharma Ltd||3,962.90||63.11||65,258.82||350.68||0.00||1,153.90||359.44|
Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in Cr.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.Lupin Ltd was incorporated in th... More
Reports by lupin-ltd-share-price
Sep 18, 2021 10:43 PM
The company’s consolidated revenue stood at Rs4,504.87cr, up 13.31% yoy and 15.78% qoq.
11 Aug 2021
15 Jul 2021
AGM 11/08/2021Proceedings at the Thirty-Ninth Annual General Meeting (AGM) pursuant to Regulation 30... More
10 Aug 2021
30 Jul 2021
LUPIN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on... More
13 May 2021
27 Jul 2021
Lupin Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 12,... More